logo

For the Inventor, By the Inventor

Epalinges, Switzerland

Jean-Charles Cerottini

This inventor holds 9 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 1998-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Charles Cerottini. Retrieved from https://idiyas.com/inventor/jean-charles-cerottini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 77.8

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 56(Granted Patents)


Location History:

  • Lausanne, CH (2003)
  • Epalinges, CH (1998 - 2010)

Company Filing History:

goldMedal9 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents

Years Active: 1998-2010

Loading Chart...
9 patents (USPTO):Explore Patents
1. 7713714 - Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof (2010-05-11),
2. 7344879 - Isolated nucleic acid molecules which encode peptides that bind to HLA molecules, and uses thereof (2008-03-18),
3. 6605711 - NY-ESO-1 peptide derivatives, and uses thereof (2003-08-12),
4. 6384190 - Isolated decapeptides which bind to HLA molecules (2002-05-07),
5. 6368857 - Method for provoking proliferation of cytolytic T cells via the use of decapeptides which complex with HLA-A2 molecules (2002-04-09),
6. 6326200 - Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof (2001-12-04),
7. 6277956 - Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof (2001-08-21),
8. 6025470 - Isolated nona- and decapeptides which bind to HLA molecules, and the use (2000-02-15),
9. 5827073 - Photoreactive peptide derivatives (1998-10-27),

Title: Innovations by Jean-Charles Cerottini

Introduction

Jean-Charles Cerottini is a prominent inventor based in Epalinges, Switzerland. He has made significant contributions to the field of cancer research, particularly in the development of peptides that interact with HLA molecules. With a total of 9 patents to his name, Cerottini's work has the potential to advance therapeutic strategies in immunology.

Latest Patents

Cerottini's latest patents include groundbreaking discoveries. One patent describes isolated nona- and decapeptides that bind to HLA molecules, along with a method for inducing the proliferation of cytolytic T cells. Another patent focuses on isolated nucleic acid molecules that encode peptides binding to HLA molecules, specifically decapeptides defined by an HLA-A2 binding motif. This patent also discloses expression vectors that incorporate these nucleic acid molecules.

Career Highlights

Cerottini is affiliated with the Ludwig Institute for Cancer Research Limited, where he conducts his research. His work has been instrumental in understanding the immune response to cancer and developing new therapeutic approaches. His innovative research has garnered attention in the scientific community, contributing to advancements in cancer immunotherapy.

Collaborations

Some of his notable coworkers include Pedro Romero and Danila Valmori. Their collaborative efforts have further enhanced the impact of Cerottini's research in the field of cancer immunology.

Conclusion

Jean-Charles Cerottini's contributions to cancer research through his innovative patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for new therapeutic strategies that could significantly improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…